Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 7/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12121682 | 0.95 | CCR1 (0.48) | CCR1DRD2CCR3ADRA1A | |
| SCHEMBL654890 | 0.90 | CCR1 (0.48) | CCR1DRD2OPRM1OPRL1CCR3 | |
| SCHEMBL654891 | 0.90 | CCR1 (0.48) | CCR1DRD2OPRM1OPRL1CCR3 | |
| SCHEMBL16312640 | 0.90 | CCR1 (0.48) | CCR1DRD2OPRM1OPRL1CCR3 | |
| SCHEMBL655738 | 0.89 | CCR3 (0.53) | CCR1DRD2OPRM1OPRL1CCR3 | |
| SCHEMBL655737 | 0.89 | CCR3 (0.53) | CCR1DRD2OPRM1OPRL1CCR3 | |
| SCHEMBL654198 | 0.88 | DRD2 (0.48) | CCR1DRD2OPRM1OPRL1CCR3 | |
| SCHEMBL654197 | 0.88 | DRD2 (0.48) | CCR1DRD2OPRM1OPRL1CCR3 | |
| SCHEMBL655897 | 0.88 | DRD2 (0.47) | CCR1DRD2OPRM1OPRL1CCR3 | |
| SCHEMBL655896 | 0.88 | DRD2 (0.47) | CCR1DRD2OPRM1OPRL1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | CCR1 10/4885DRD2 3566/4885OPRM1 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.